Previous Article | Next Article 
J Virol, July 1998, p. 6113-6118, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
The Orphan Seven-Transmembrane Receptor Apj
Supports the Entry of Primary T-Cell-Line-Tropic and Dualtropic Human
Immunodeficiency Virus Type 1
Hyeryun
Choe,1,2
Michael
Farzan,1,2
Miriam
Konkel,1,2
Kathleen
Martin,3,4
Ying
Sun,1,2
Luisa
Marcon,1,2
Mark
Cayabyab,1,2,3
Michael
Berman,2
Martin E.
Dorf,2
Norma
Gerard,3,4
Craig
Gerard,3,4 and
Joseph
Sodroski1,2,5,*
Division of Human Retrovirology, Dana-Farber
Cancer Institute,1
Department of
Pathology, Harvard Medical School,2
Perlmutter Laboratory, Children's
Hospital,3
Departments of Medicine and
Pediatrics, Beth Israel Hospital and Harvard Medical
School,4 and
Department of Immunology
and Infectious Diseases, Harvard School of Public
Health,5 Boston, Massachusetts 02115
Received 16 January 1998/Accepted 6 April 1998
 |
ABSTRACT |
Human immunodeficiency virus type 1 (HIV-1) enters target cells by
sequential binding to CD4 and specific seven-transmembrane-segment (7TMS) coreceptors. Viruses use the chemokine receptor CCR5 as a
coreceptor in the early, asymptomatic stages of HIV-1 infection but can
adapt to the use of other receptors such as CXCR4 and CCR3 as the
infection proceeds. Here we identify one such coreceptor, Apj, which
supported the efficient entry of several primary T-cell-line tropic
(T-tropic) and dualtropic HIV-1 isolates and the simian immunodeficiency virus SIVmac316. Another 7TMS protein, CCR9, supported
the less efficient entry of one primary T-tropic isolate. mRNAs for
both receptors were present in phytohemagglutinin- and interleukin-2-activated peripheral blood mononuclear cells. Apj and
CCR9 share with other coreceptors for HIV-1 and SIV an N-terminal region rich in aromatic and acidic residues. These results highlight properties common to 7TMS proteins that can function as HIV-1 coreceptors, and they may contribute to an understanding of viral evolution in infected individuals.
 |
INTRODUCTION |
The human immunodeficiency viruses
type 1 and type 2 (HIV-1 and HIV-2) are the etiologic agents of AIDS,
which results from the depletion of CD4-positive T lymphocytes (3,
15, 17). HIV-1 infects T lymphocytes, monocytes/macrophages,
dendritic cells, and microglial cells in the central nervous system.
Efficient entry of HIV-1 into these cells is dependent on the binding
of the viral envelope protein gp120 to the cellular receptor CD4 and
subsequently to one of several seven-transmembrane-segment (7TMS)
receptors (1, 5, 7, 8, 10, 11, 16, 22). Most of the known
7TMS receptors that serve as HIV-1 coreceptors have as their natural
ligands members of the chemokine family. In addition, several orphan
receptors, some of which are only distantly related to chemokine
receptors, support the entry of various simian immunodeficiency viruses
(SIV) and less efficient entry of some HIV-1 isolates (2, 9, 12,
21).
HIV-1 isolates are usually described in terms of their cellular tropism
and passage history (5). Macrophage-tropic (M-tropic) viruses infect macrophages and primary T cells but not most
immortalized T-cell lines. Dualtropic viruses can infect macrophages,
primary T cells, and T-cell lines. T-cell line-tropic (T-tropic)
viruses can infect primary T cells and T-cell lines but not primary
macrophages. T-tropic viruses can be usefully divided into those that
have been extensively passaged in laboratory cell lines
(laboratory-adapted T-tropic viruses) and those that have been
molecularly cloned after only limited in vitro passage (primary
T-tropic viruses). HIV tropism is strongly correlated with coreceptor
use. M-tropic viruses mainly use CCR5 as a coreceptor, although some
M-tropic viruses can also use CCR3. The laboratory-adapted T-tropic
viruses mainly use CXCR4 as a coreceptor. Most dualtropic and primary T-tropic viruses use CCR5, CXCR4, CCR3, and other receptors with different levels of efficiency (5, 10, 21).
Alanine-scanning mutagenesis of the exterior domains of CCR5 had shown
that a small region in the N terminus of CCR5, rich in tyrosines and
acidic residues, plays an important role in infection by HIV-1 and SIV
isolates using this coreceptor (14). The presence of a
similar array of residues in the N termini of two orphan 7TMS receptors
helped to identify these receptors as efficient coreceptors for SIV
(12). Here we show that a previously cloned 7TMS receptor,
Apj (27), is expressed in the brain and in
phytohemagglutinin (PHA)- and interleukin-2 (IL-2)-activated peripheral
blood mononuclear cells (PBMC) and supports the efficient entry of
recombinant HIV-1 pseudotyped with the envelope glycoproteins of
several primary HIV-1 isolates. Apj also contains an array of aromatic
and acidic residues in its N terminus that are similar to those of
CXCR4, CCR3, and CCR5, although it has much higher overall sequence
similarity to the angiotensin receptors I and II than to any known
chemokine receptor (27). CCR9 (26), a newly
identified 7TMS receptor with a similar array of tyrosines, less
efficiently supported the entry of only 1 recombinant primary T-tropic
virus of 10 isolates tested. These results underscore the importance of
residues in the N terminus of coreceptor molecules for primary T-tropic
as well as M-tropic viruses, and they may contribute to an
understanding of HIV-1 evolution in the host.
 |
MATERIALS AND METHODS |
Plasmids.
Plasmids pHXBH10
envCAT and pSVIIIenv, used to
produce recombinant HIV-1 virions containing the envelope glycoproteins
from the HIV-1 isolates ADA, YU2, JR-FL, 89.6, ELI, UG21, MN, and HXB2 or the envelope glycoproteins from SIV isolates SIVmac239 and SIVmac316, have been described previously (5, 18, 20, 23, 25,
30). Plasmid pCD4, used to express full-length CD4 in Cf2Th
cells, has been described elsewhere (4). CCR5, CCR3, CCR2b,
CXCR4, and gpr15 in the expression vector pcDNA3 (Invitrogen) have been
described previously (5, 12). CCR8 and HA-tagged CCR8 in the
pcDNA3 plasmid were provided by Monica Napolitano. US28 was expressed
in a pCEP4 vector (Invitrogen). Strl33 was isolated from a T-cell cDNA
library described previously (12) and cloned into the pcDNA3
vector. An additional plasmid encoding Strl33 in a pCEP4 vector was
provided by Joshua Farber (21). Apj and CCR9 were cloned
from human brain QUICK-Clone cDNA (Clonetech) and QUICK-Clone MOLT-4
cDNA (Clontech), respectively, and subcloned into pcDNA3.
Cell lines.
Cf2Th canine thymocytes (ATCC CCRL 1430) were
obtained from the American Type Culture Collection. Cells were
maintained as described previously (5). Cf2Th-CD4 cells were
generated by transfection with the expressor plasmid pcDNA3.1
(Invitrogen) encoding CD4, selection with 0.1 mg/ml hygromycin, and
cloning by limiting dilution.
env complementation assay.
A single round of
HIV-1 infection was assayed in a previously described env
complementation assay (5). Briefly, recombinant HIV-1 with
the nef gene replaced by a gene encoding chloramphenicol acetyltransferase (CAT) was pseudotyped with various HIV-1 and SIV
envelope glycoproteins and used to infect Cf2Th or Cf2Th-CD4 cells. The
target cells had been transfected, 48 h before infection, by the
calcium phosphate method with either 10 µg of plasmid encoding CD4
and 20 µg of plasmid encoding a 7TMS receptor (Cf2Th), or 25 µg of
plasmid encoding a 7TMS receptor (Cf2Th-CD4). For these assays, 25,000 cpm of reverse transcriptase activity of the recombinant viruses
containing the envelope glycoproteins of YU2, ADA, JR-FL, 89.6, ELI,
UG21, MN, HXB2, SIVmac239, or SIVmac316 was incubated at 37°C with
Cf2Th target cells expressing various 7TMS molecules. Cells were lysed
72 h after infection, and CAT activity was measured, indicating
the efficiency of infection.
Detection of mRNA encoding Apj and CCR9.
The mRNA from PBMC
activated with 5 µg of PHA per ml, with or without 20 U of IL-2 per
ml added 48 h later, was isolated and reverse transcribed as
previously described (12). The cDNAs for Apj and CCR9 were
detected by PCR. QUICK-clone brain, thymus, and spleen cDNAs
(Clonetech) were also used to identify the presence of Apj and CCR9.
Quantitation of viral replication.
Replication-competent
89.6 or ELI virus was made by transfecting HeLa cells or 293T cells,
respectively, by the calcium phosphate method with plasmids containing
the proviral genome. Replication-competent virus was harvested 72 h after transfection and incubated with CF2Th cells 48 h after
transfection of these cells with a plasmid expresing CD4 and either
pcDNA3 or plasmids encoding Apj and CXCR4, in the presence or absence
of 50 µM azidothymidine. Four days after infection, the
p24gag protein was detected with an HIV-1 p24
enzyme-linked immunosorbent assay kit (Dupont Medical Products) as
specified by the manufacturer.
 |
RESULTS |
We investigated the properties of two human 7TMS receptors whose N
termini exhibited sequence similarity to the N termini of CCR5 and/or
CXCR4. Both the orphan receptor Apj and CCR9, whose murine counterpart
binds murine MIP-1
and MIP-1
(26), possess N-terminal
tyrosines that could be aligned with the tyrosines shown to be
important for the ability of CCR5 to support HIV-1 and SIV entry
(14). Figure 1 demonstrates
that both Apj and CCR9 can serve as coreceptors for the entry of some
HIV-1 or SIV isolates. As previously reported (5), virus
pseudotyped with the envelope glycoproteins from M-tropic HIV-1
isolates (ADA, JR-FL, and YU2), a dualtropic HIV-1 isolate (89.6), or
SIV isolates (SIVmac239 and SIVmac316) could efficiently enter
Cf2Th-CD4 cells expressing CCR5. Also as expected, Cf2Th-CD4 cells
expressing CXCR4 supported the entry of a dualtropic HIV-1 isolate
(89.6), primary T-tropic HIV-1 isolates (ELI and UG21),
laboratory-adapted T-tropic HIV-1 isolates (HXBc2 and MN), and, very
inefficiently, SIVmac316. The same viruses were used to infect Cf2Th
cells expressing CD4 and either Apj or CCR9. Cells expressing CD4 and
Apj supported the entry of a primary dualtropic HIV-1 isolate (89.6),
primary T-tropic HIV-1 isolates (ELI and UG21), and, to a lesser
extent, laboratory-adapted T-tropic HIV-1 isolates (MN and HXB2).
Interestingly, SIVmac316, which is derived from a rhesus macaque
infected with SIVmac239 (25), can also infect cells
expressing CD4 and Apj, although SIVmac239 does so only weakly. CCR9
was able to support the entry of virus pseudotyped with the envelope
glycoproteins of the primary T-tropic HIV-1 isolate, UG21, but also
demonstrated signals above those seen for the control cells expressing
only CD4 when viruses containing the 89.6, ELI, or SIVmac316 envelope glycoproteins were tested.

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 1.
Dualtropic and T-tropic viruses use Apj or CCR9 as
coreceptors. Cf2Th-CD4 cells were transfected with either the pcDNA3
vector only or pcDNA3 plasmids encoding CCR5, CXCR4, Apj, or CCR9. The
transfected cells were incubated with recombinant CAT-expressing
viruses containing the envelope glycoproteins of the M-tropic HIV-1
ADA, JR-FL, or YU2; the dualtropic HIV-1 89.6; the primary T-tropic
HIV-1 ELI, or UG21; the laboratory-adapted T-tropic HIV-1 MN or HXBc2;
or the SIV isolates SIVmac239 or SIVmac316. Entry was quantitated as
the ratio of the acetylated forms of chloramphenicol (upper spots) to
the unacetylated form (bottom spot). Samples in which conversion is
greater than 60% were diluted 1:10 and reassayed for quantitative
comparisons. Entry of viruses pseudotyped with 89.6, ELI, UG21, MN, or
HXBc2 envelope glycoproteins into cells expressing Apj was 5.6 ± 0.2, 10.2 ± 0.1, 7.7 ± 0.4, 1.5, and 0.3% ± 0.1%,
respectively, of that of the same viruses entering cells expressing
CXCR4. The entry of the virus pseudotyped with the envelope
glycoproteins of SIVmac316 into cells expressing Apj was 21.9% ± 4.7% of that observed for cells expressing CCR5. Entry of virus
pseudotyped with UG21 envelope glycoproteins into cells expressing CCR9
was 6.2% ± 1.9% of that observed for cells expressing CXCR4.
|
|
To assess the potential physiological relevance of these observations,
we sought to determine whether Apj and CCR9 were present in PBMC
stimulated with PHA or with PHA plus IL-2. Figure
2 shows that cDNAs for both CCR9 and Apj
were detected in PBMC that had been activated with PHA plus IL-2 but
only weak signals were seen for PBMC that had been stimulated with PHA
alone. No signal was detected for either receptor if reverse
transcriptase was excluded from the mRNA preparations used to generate
cDNA, indicating that these signals were not derived from contaminating
genomic DNA. We also detected Apj in preparations of cDNA from spleen
and from brain (data not shown); the latter observation is consistent
with previous reports (24, 27) and our own ability to clone
Apj from brain cDNA. CCR9 was detectable in cDNA prepared from the thymus (data not shown).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 2.
Expression of Apj and CCR9 in PBMC. mRNA was isolated
from PBMC activated with PHA (right-hand lanes) or with PHA plus IL-2
(left-hand lanes) and reverse transcribed to cDNA. PCR was performed
with primers bounding an approximately 1,100-bp fragment of the Apj or
CCR9 gene, or a 200-bp fragment of the -globin gene control. In the
lanes labeled RT , the PCR was performed with the same reaction mixes
used in the other two lanes, but prepared without reverse
transcriptase.
|
|
The ability of Apj and CCR9 to support virus entry was compared with
that of a number of receptors previously reported to exhibit HIV and/or
SIV coreceptor activity, by using a smaller panel of viruses. Figure
3 shows that entry of some HIV-1 isolates into Cf2Th cells expressing CD4 and CXCR4 or CD4 and CCR5 was efficient, as was SIV entry into Cf2Th cells expressing CD4 and Strl33,
CCR5, or gpr15. These levels of entry were nearly 10-fold higher than
those observed for the next most efficient receptors, Apj and CCR3.
Although specific reagents were not available to normalize for the cell
surface expression of receptors, some conclusions can be drawn. CCR2b
only weakly supports the entry of one virus, 89.6, a result
quantitatively consistent with the first report of CCR2b use
(10). Signaling and binding experiments by MCP-1 on 293T
cells have previously demonstrated that the CCR2b construct used here
can be expressed efficiently in these cells (13). Consistent
with previous reports, CCR3 can support the entry of M-tropic (ADA),
dualtropic (89.6), and primary T-tropic (ELI) HIV-1 at efficiencies
ranging from 5 to 10% of those of the entry of the same viruses when
either CCR5 (ADA and 89.6) or CXCR4 (ELI) is used. Slightly higher
levels of entry into cells expressing Apj were detected for 89.6 and
ELI viruses. Values only slightly above background were detected for
the entry of HIV-1 isolates into cells expressing CD4 and CCR8, Strl33,
or the cytomegalovirus-encoded 7TMS receptor, US28. These results are
not quantitatively consistent with other reports of HIV-1 entry on
these receptors (21, 28, 29), a discrepancy that may be
accounted for by differences in the level of coreceptor expression
achieved. However, expression of the identical US28 construct was
verified on transfected 293T cells by using MIP-1
binding (data not
shown). Some of the reported discrepancies may arise from the use of
assay systems in which entry into cells expressing CCR5 or CXCR4 is
saturated, thus exaggerating the relative efficiency of other
receptors. Although care must be taken when comparing virus entry into
cells expressing different receptors, we conclude that Apj is a
relatively efficient receptor for dualtropic and primary T-tropic HIV-1
isolates. Figure 4 demonstrates that Apj
can serve as an efficient coreceptor for primary dualtropic viruses in
an assay system involving replication-competent viruses.

View larger version (93K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of virus entry by using Apj or other reported
coreceptors. Cf2Th cells were transfected with a plasmid expressing CD4
and the pcDNA3 vector or plasmid expressing the indicated 7TMS receptor
and incubated with recombinant viruses containing the ADA, 89.6, ELI,
HXBc2, SIVmac239, or SIVmac316 envelope glycoproteins. CAT expression
was analyzed in the target cells as described in Materials and
Methods.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Apj supports the entry of replication-competent viruses.
Replication-competent ELI (A) and 89.6 (B) HIV-1 isolates were
incubated with Cf2Th cells transfected with CD4 and either a control
plasmid or plasmids encoding Apj or CXCR4, in the presence or absence
of 50 µM azidothymidine (AZT). The p24 values from 4 days after
infection are given in picograms per milliliter, with a 1:5 dilution of
cell supernatant.
|
|
 |
DISCUSSION |
During the course of HIV-1 infection, viruses emerge that use a
broader range of coreceptors (6), including CXCR4, CCR3, CCR2b, and, as shown here, Apj. These dualtropic and primary T-tropic viruses probably infect a broader range of target cells, and their emergence may coincide with an accelerated disease progression. The
ability of SIVmac316, but not SIVmac239, to use Apj as a coreceptor demonstrates that this expansion of receptor use may occur within SIV-infected rhesus macaques as well. SIVmac316 is derived from a
macaque infected with SIVmac239 that had developed AIDS-like symptoms
(25). The relative efficiency with which Apj is used as a
coreceptor by primary viruses and its expression on activated PBMC
suggest that it may play a role in viral dissemination in HIV-infected
individuals. Moreover, the lower efficiency of Apj use by
laboratory-adapted viruses, compared with primary T-tropic viruses, may
suggest that Apj-using viruses are selected in vivo but not in vitro in
humans as well as in macaques.
M-tropic HIV-1 isolates that have been isolated from the central
nervous system have been shown to use CCR3, as well as CCR5, as a
coreceptor (5, 19). Both CCR3 and CCR5 are present on the
surface of brain microglia, and infection of fetal brain cultures by
these isolates has been demonstrated (19). Apj is also
expressed in brain tissue and has sequence similarity to CCR5 and CCR3
in an N-terminal region of these molecules that has been shown to be
important for coreceptor function (14). However, neither of
the tested central nervous system-derived M-tropic viruses, JR-FL or
YU2, can use Apj as a coreceptor, although both use CCR3. It remains to
be determined whether there is a specific role for Apj as a coreceptor
in the central nervous system following the emergence of dualtropic or
T-tropic viruses.
The identification of Apj and CCR9 as HIV-1 coreceptors supports
earlier observations indicating that a specific array of tyrosines and
acidic amino acids in the N termini of these molecules plays a critical
role in infection by HIV-1 and SIV (14). Single-amino-acid changes in this region of CCR5 interfere with the ability of primary M-tropic and dualtropic HIV-1 and with SIVmac239 to infect cells expressing these mutants. The amino termini of three alternate SIV
coreceptors, Strl33, gpr15, and gpr1, exhibit sequence similarity to
this region of CCR5. The results described above suggest that primary
T-tropic HIV-1 isolates may also require the presence of specific
N-terminal tyrosines in their coreceptors. The tyrosine-rich, acidic
motif is less well developed in CXCR4 than in CCR5, with the Apj N
terminus sharing characteristics of both sequences (Fig. 5a). Apj and CCR3 could facilitate the
adaptation of CCR5-using viruses to CXCR4 by providing an N terminus
that diverges from that of CCR5 and possesses similarity to that of
CXCR4. Further adaptation to CXCR4 could require increased dependence
on other regions of the molecule, including the second extracellular
loop (29). Figure 5b summarizes coreceptor usage data for
CCR5, CCR3, Apj, and CXCR4.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 5.
7TMS receptor sequences and coreceptor function. (a)
Alignment of CCR5, Apj, and CXCR4 N-terminal sequences. The sequences
of the N termini, beginning with the initiator methiones, of CCR5, Apj,
and CXCR4 are shown. Tyrosines 10, 14, and 15, aspartic acid 11, asparagine 13, and glutamic acid 18 of CCR5 have been previously
demonstrated to be important for M-tropic and dualtropic viral entry by
using CCR5 (14). Common residues are shown in boldface type,
and possible N-linked glycosylation sites are underlined. Also shown is
the N terminus of CCR9, with a tyrosine-rich region indicated in bold.
(B) Summary of the coreceptor usage of various HIV-1 isolates. The
ability of various HIV-1 isolates to enter Cf2Th cells expressing CD4
and each of the four coreceptors shown to be most efficient in this
study is indicated by shaded bars. Stars indicate relatively
inefficient entry of laboratory-adapted T-tropic viruses into cells
expressing the Apj receptor.
|
|
CCR9 also possesses a prominent array of tyrosines in its N terminus
(Fig. 5a) yet supports the entry of only a single virus of 10 tested.
Whether subtleties in the arrangement of these tyrosines, or other
properties of the molecule, limit its ability to function as an
efficient coreceptor remains to be demonstrated.
The contribution of HIV-1 coreceptors other than CCR5, CXCR4, and
perhaps, CCR3 to natural infection and pathogenesis remains unclear.
The efficiency of Apj coreceptor function relative to that of most of
the other reported HIV-1 coreceptors, its use by a range of dualtropic
and primary T-tropic viruses, and its presence in activated PBMC and in
the central nervous system suggest that further examination of its role
is warranted.
 |
ACKNOWLEDGMENTS |
The first two authors contributed equally to this work.
This work was supported by grants to Joseph Sodroski from the National
Institutes of Health (AI 24755 and AI 41851) and by a Center for AIDS
Research grant to the Dana-Farber Cancer Institute (AI 28691).
Dana-Farber Cancer Institute is also the recipient of a Cancer Center
grant from the National Institutes of Health (CA 06516). Craig Gerard
was supported by NIH grants HL 51366 and AI 36162, as well as by the
Rubenstein/Cable Fund at the Perlmutter Laboratory. Martin Dorf was
supported by an NIH grant (NS 37284). Mark Cayabyab is a recipient of a
Ford Foundation Fellowship. Michael Farzan was supported by a training
grant (CA 09141). This work was made possible by gifts from the late
William McCarty-Cooper, from the G. Harold and Leila Y. Mathers
Charitable Foundation, and from the Friends 10.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: JFB 824, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115. Phone:
(617) 632-3371. Fax: (617) 632-4338. E-mail:
joseph_sodroski{at}dfci.harvard.edu.
 |
REFERENCES |
| 1.
|
Alkhatib, G.,
C. Combadiere,
C. C. Broder,
Y. Feng,
P. E. Kennedy,
P. M. Murphy, and E. A. Berger.
1996.
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.
Science
272:1955-1958[Abstract].
|
| 2.
|
Alkhatib, G.,
F. Liao,
E. A. Berger,
J. M. Farber, and K. W. Peden.
1997.
A new SIV co-receptor, STRL33.
Nature
388:238[Medline]. (Letter.)
|
| 3.
|
Barre-Sinoussi, F.,
J. C. Chermann,
F. Rey,
M. T. Nugeyre,
S. Chamaret,
J. Gruest,
C. Dauguet,
C. Axler-Blin,
F. Vezinet-Brun,
C. Rouzioux,
W. Rozenbaum, and L. Montagnier.
1983.
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).
Science
220:868-871[Abstract/Free Full Text].
|
| 4.
|
Brand, D.,
K. Srinivasan, and J. Sodroski.
1995.
Determinants of human immunodeficiency virus type 1 entry in the CDR2 loop of the CD4 glycoprotein.
J. Virol.
69:166-171[Abstract].
|
| 5.
|
Choe, H.,
M. Farzan,
Y. Sun,
N. Sullivan,
B. Rollins,
P. D. Ponath,
L. Wu,
C. R. Mackay,
G. LaRosa,
W. Newman,
N. Gerard,
C. Gerard, and J. Sodroski.
1996.
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
Cell
85:1135-1148[Medline].
|
| 6.
|
Connor, R. I.,
K. E. Sheridan,
D. Ceradini,
S. Choe, and N. R. Landau.
1997.
Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals.
J. Exp. Med.
185:621-628[Abstract/Free Full Text].
|
| 7.
|
Dalgleish, A. G.,
P. C. Beverley,
P. R. Clapham,
D. H. Crawford,
M. F. Greaves, and R. A. Weiss.
1984.
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
Nature
312:763-767[Medline].
|
| 8.
|
Deng, H.,
R. Liu,
W. Ellmeier,
S. Choe,
D. Unutmaz,
M. Burkhart,
P. Di Marzio,
S. Marmon,
R. E. Sutton,
C. M. Hill,
C. B. Davis,
S. C. Peiper,
T. J. Schall,
D. R. Littman, and N. R. Landau.
1996.
Identification of a major co-receptor for primary isolates of HIV-1.
Nature
381:661-666[Medline].
|
| 9.
|
Deng, H. K.,
D. Unutmaz,
V. N. KewalRamani, and D. R. Littman.
1997.
Expression cloning of new receptors used by simian and human immunodeficiency viruses.
Nature
388:296-300[Medline].
|
| 10.
|
Doranz, B. J.,
J. Rucker,
Y. Yi,
R. J. Smyth,
M. Samson,
S. C. Peiper,
M. Parmentier,
R. G. Collman, and R. W. Doms.
1996.
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.
Cell.
85:1149-1158[Medline].
|
| 11.
|
Dragic, T.,
V. Litwin,
G. P. Allaway,
S. R. Martin,
Y. Huang,
K. A. Nagashima,
C. Cayanan,
P. J. Maddon,
R. A. Koup,
J. P. Moore, and W. A. Paxton.
1996.
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC- CKR-5.
Nature
381:667-673[Medline].
|
| 12.
|
Farzan, M.,
H. Choe,
K. Martin,
L. Marcon,
W. Hofmann,
G. Karlsson,
Y. Sun,
P. Barrett,
N. Marchand,
N. Sullivan,
N. Gerard,
C. Gerard, and J. Sodroski.
1997.
Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection.
J. Exp. Med.
186:405-411[Abstract/Free Full Text].
|
| 13.
|
Farzan, M.,
H. Choe,
K. A. Martin,
Y. Sun,
M. Sidelko,
C. R. Mackay,
N. P. Gerard,
J. Sodroski, and C. Gerard.
1997.
HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5.
J. Biol. Chem.
272:6854-6857[Abstract/Free Full Text].
|
| 14.
|
Farzan, M.,
H. Choe,
L. Vaca,
K. Martin,
Y. Sun,
E. Desjardins,
N. Huffing,
L. Wu,
R. Wyatt,
N. Gerard,
C. Gerard, and J. Sodroski.
1998.
A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5.
J. Virol.
72:1160-1164[Abstract/Free Full Text].
|
| 15.
|
Fauci, A. S.,
A. M. Macher,
D. L. Longo,
H. C. Lane,
A. H. Rook,
H. Masur, and E. P. Gelmann.
1984.
NIH Conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations.
Ann. Intern. Med.
100:92-106.
|
| 16.
|
Feng, Y.,
C. C. Broder,
P. E. Kennedy, and E. A. Berger.
1996.
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
Science
272:872-877[Abstract].
|
| 17.
|
Gallo, R. C.,
S. Z. Salahuddin,
M. Popovic,
G. M. Shearer,
M. Kaplan,
B. F. Haynes,
T. J. Palker,
R. Redfield,
J. Oleske,
B. Safai, et al.
1984.
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.
Science
224:500-503[Abstract/Free Full Text].
|
| 18.
|
Gao, F.,
S. G. Morrison,
D. L. Robertson,
C. L. Thornton,
S. Craig,
G. Karlsson,
J. Sodroski,
M. Morgado,
B. Galvao-Castro,
H. von Briesen,
S. Beddows,
J. Weber,
P. M. Sharp,
G. M. Shaw, and B. H. Hahn.
1996.
Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.
J. Virol.
70:1651-1667[Abstract].
|
| 19.
|
He, J.,
Y. Chen,
M. Farzan,
H. Choe,
A. Ohagen,
S. Gartner,
J. Busciglio,
X. Yang,
W. Hofmann,
W. Newman,
C. R. Mackay,
J. Sodroski, and D. Gabuzda.
1997.
CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.
Nature
385:645-649[Medline].
|
| 20.
|
Helseth, E.,
M. Kowalski,
D. Gabuzda,
U. Olshevsky,
W. Haseltine, and J. Sodroski.
1990.
Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants.
J. Virol.
64:2416-2420[Abstract/Free Full Text].
|
| 21.
|
Liao, F.,
G. Alkhatib,
K. W. Peden,
G. Sharma,
E. A. Berger, and J. M. Farber.
1997.
STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1.
J. Exp. Med.
185:2015-2023[Abstract/Free Full Text].
|
| 22.
|
Maddon, P. J.,
A. G. Dalgleish,
J. S. McDougal,
P. R. Clapham,
R. A. Weiss, and R. Axel.
1986.
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.
Cell
47:333-348[Medline].
|
| 23.
|
Marcon, L.,
H. Choe,
K. A. Martin,
M. Farzan,
P. D. Ponath,
L. Wu,
W. Newman,
N. Gerard,
C. Gerard, and J. Sodroski.
1997.
Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239.
J. Virol.
71:2522-2527[Abstract].
|
| 24.
|
Matsumoto, M.,
K. Hidaka,
H. Akiho,
S. Tada,
M. Okada, and T. Yamaguchi.
1996.
Low stringency hybridization study of the dopamine D4 receptor revealed D4-like mRNA distribution of the orphan seven-transmembrane receptor, APJ, in human brain.
Neurosci. Lett.
219:119-122[Medline].
|
| 25.
|
Mori, K.,
D. Ringler, and R. Desrosiers.
1992.
Restricted replication of SIVmac239 in macrophages is determined by env but is not due to restricted entry, abstr. 19.
In
Tenth Symposium on Nonhum Primate Models of AIDS.
|
| 26.
|
Nibbs, R. J. B.,
S. M. Wylie,
I. B. Pragnell, and G. J. Graham.
1997.
Cloning and characterization of a novel murine beta chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1alpha receptors, CCR-1, CCR-3, and CCR-5.
J. Biol. Chem.
272:12495-12504[Abstract/Free Full Text].
|
| 27.
|
O'Dowd, B. F.,
M. Heiber,
A. Chan,
H. H. Heng,
L. C. Tsui,
J. L. Kennedy,
X. Shi,
A. Petronis,
S. R. George, and T. Nguyen.
1993.
A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11.
Gene
136:355-360[Medline].
|
| 28.
|
Pleskoff, O.,
C. Treboute,
A. Brelot,
N. Heveker,
M. Seman, and M. Alizon.
1997.
Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry.
Science
276:1874-1878[Abstract/Free Full Text].
|
| 29.
|
Rucker, J.,
A. L. Edinger,
M. Sharron,
M. Samson,
B. Lee,
J. Berson,
Y. Yi,
B. Margulies,
R. G. Collman,
B. J. Doranz,
M. Parmentier, and R. W. Doms.
1997.
Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses.
J. Virol.
71:8999-9007[Abstract].
|
| 30.
|
Sullivan, N.,
Y. Sun,
J. Li,
W. Hofmann, and J. Sodroski.
1995.
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.
J. Virol.
69:4413-4422[Abstract].
|
J Virol, July 1998, p. 6113-6118, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Nedellec, R., Coetzer, M., Shimizu, N., Hoshino, H., Polonis, V. R., Morris, L., Martensson, U. E. A., Binley, J., Overbaugh, J., Mosier, D. E.
(2009). Virus Entry via the Alternative Coreceptors CCR3 and FPRL1 Differs by Human Immunodeficiency Virus Type 1 Subtype. J. Virol.
83: 8353-8363
[Abstract]
[Full Text]
-
Agrawal, L., Maxwell, C. R., Peters, P. J., Clapham, P. R., Liu, S. M., Mackay, C. R., Strayer, D. S.
(2009). Complexity in human immunodeficiency virus type 1 (HIV-1) co-receptor usage: roles of CCR3 and CCR5 in HIV-1 infection of monocyte-derived macrophages and brain microglia. J. Gen. Virol.
90: 710-722
[Abstract]
[Full Text]
-
Shimizu, N., Tanaka, A., Oue, A., Mori, T., Apichartpiyakul, C., Hoshino, H.
(2008). A short amino acid sequence containing tyrosine in the N-terminal region of G protein-coupled receptors is critical for their potential use as co-receptors for human and simian immunodeficiency viruses. J. Gen. Virol.
89: 3126-3136
[Abstract]
[Full Text]
-
Masri, B., Morin, N., Pedebernade, L., Knibiehler, B., Audigier, Y.
(2006). The Apelin Receptor Is Coupled to Gi1 or Gi2 Protein and Is Differentially Desensitized by Apelin Fragments. J. Biol. Chem.
281: 18317-18326
[Abstract]
[Full Text]
-
Gray, L., Churchill, M. J., Keane, N., Sterjovski, J., Ellett, A. M., Purcell, D. F. J., Poumbourios, P., Kol, C., Wang, B., Saksena, N. K., Wesselingh, S. L., Price, P., French, M., Gabuzda, D., Gorry, P. R.
(2006). Genetic and Functional Analysis of R5X4 Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Derived from Two Individuals Homozygous for the CCR5{Delta}32 Allele.. J. Virol.
80: 3684-3691
[Abstract]
[Full Text]
-
Crowley, S., Gurley, S., Oliverio, M., Pazmino, A., Griffiths, R, Flannery, P., Spurney, R., Kim, H-S, Smithies, O, Le, T., Coffman, T., Boucher, J, Masri, B, Daviaud, D, Gesta, S, Guigne, C, Mazzucotelli, A, Castan-Laurell, I, Tack, I, Knibiehler, B, Carpene, C, Audigier, Y, Saulnier-Blache, J., Valet, P, Engeli, S, Bohnke, J, Gorzelniak, K, Janke, J, Schling, P, Bader, M, Luft, F, Sharma, A.
(2005). Is the Kidney Always the Cause of Hypertension?: Distinct Roles for the Kidney and Systemic Tissues in Blood Pressure Regulation by the Renin-Angiotensin System. J Clin Invest 115: 1092-1099, 2005. J. Am. Soc. Nephrol.
16: 1525-1532
[Full Text]
-
Blaak, H., Boers, P. H. M., Gruters, R. A., Schuitemaker, H., van der Ende, M. E., Osterhaus, A. D. M. E.
(2005). CCR5, GPR15, and CXCR6 Are Major Coreceptors of Human Immunodeficiency Virus Type 2 Variants Isolated from Individuals with and without Plasma Viremia. J. Virol.
79: 1686-1700
[Abstract]
[Full Text]
-
Lee, D. K., Lanca, A. J., Cheng, R., Nguyen, T., Ji, X. D., Gobeil, F. Jr., Chemtob, S., George, Susan. R., O'Dowd, B. F.
(2004). Agonist-independent Nuclear Localization of the Apelin, Angiotensin AT1, and Bradykinin B2 Receptors. J. Biol. Chem.
279: 7901-7908
[Abstract]
[Full Text]
-
Forte, S., Harmon, M.-E., Pineda, M. J., Overbaugh, J.
(2003). Early- and Intermediate-Stage Variants of Simian Immunodeficiency Virus Replicate Efficiently in Cells Lacking CCR5. J. Virol.
77: 9723-9727
[Abstract]
[Full Text]
-
Willey, S. J., Reeves, J. D., Hudson, R., Miyake, K., Dejucq, N., Schols, D., Clercq, E. D., Bell, J., McKnight, A., Clapham, P. R.
(2003). Identification of a Subset of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus Strains Able To Exploit an Alternative Coreceptor on Untransformed Human Brain and Lymphoid Cells. J. Virol.
77: 6138-6152
[Abstract]
[Full Text]
-
Farzan, M., Chung, S., Li, W., Vasilieva, N., Wright, P. L., Schnitzler, C. E., Marchione, R. J., Gerard, C., Gerard, N. P., Sodroski, J., Choe, H.
(2002). Tyrosine-sulfated Peptides Functionally Reconstitute a CCR5 Variant Lacking a Critical Amino-terminal Region. J. Biol. Chem.
277: 40397-40402
[Abstract]
[Full Text]
-
Farzan, M., Babcock, G. J., Vasilieva, N., Wright, P. L., Kiprilov, E., Mirzabekov, T., Choe, H.
(2002). The Role of Post-translational Modifications of the CXCR4 Amino Terminus in Stromal-derived Factor 1alpha Association and HIV-1 Entry. J. Biol. Chem.
277: 29484-29489
[Abstract]
[Full Text]
-
Clapham, P. R., McKnight, A.
(2002). Cell surface receptors, virus entry and tropism of primate lentiviruses. J. Gen. Virol.
83: 1809-1829
[Abstract]
[Full Text]
-
Zhou, N., Luo, Z., Luo, J., Fan, X., Cayabyab, M., Hiraoka, M., Liu, D., Han, X., Pesavento, J., Dong, C.-Z., Wang, Y., An, J., Kaji, H., Sodroski, J. G., Huang, Z.
(2002). Exploring the Stereochemistry of CXCR4-Peptide Recognition and Inhibiting HIV-1 Entry with D-Peptides Derived from Chemokines. J. Biol. Chem.
277: 17476-17485
[Abstract]
[Full Text]
-
Naif, H. M., Cunningham, A. L., Alali, M., Li, S., Nasr, N., Buhler, M. M., Schols, D., de Clercq, E., Stewart, G.
(2002). A Human Immunodeficiency Virus Type 1 Isolate from an Infected Person Homozygous for CCR5{Delta}32 Exhibits Dual Tropism by Infecting Macrophages and MT2 Cells via CXCR4. J. Virol.
76: 3114-3124
[Abstract]
[Full Text]
-
Gorry, P. R., Bristol, G., Zack, J. A., Ritola, K., Swanstrom, R., Birch, C. J., Bell, J. E., Bannert, N., Crawford, K., Wang, H., Schols, D., De Clercq, E., Kunstman, K., Wolinsky, S. M., Gabuzda, D.
(2001). Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity. J. Virol.
75: 10073-10089
[Abstract]
[Full Text]
-
Sabbe, R., Picchio, G. R., Pastore, C., Chaloin, O., Hartley, O., Offord, R., Mosier, D. E.
(2001). Donor- and Ligand-Dependent Differences in C-C Chemokine Receptor 5 Reexpression. J. Virol.
75: 661-671
[Abstract]
[Full Text]
-
Cayabyab, M., Hinuma, S., Farzan, M., Choe, H., Fukusumi, S., Kitada, C., Nishizawa, N., Hosoya, M., Nishimura, O., Messele, T., Pollakis, G., Goudsmit, J., Fujino, M., Sodroski, J.
(2000). Apelin, the Natural Ligand of the Orphan Seven-Transmembrane Receptor APJ, Inhibits Human Immunodeficiency Virus Type 1 Entry. J. Virol.
74: 11972-11976
[Abstract]
[Full Text]
-
Bannert, N., Schenten, D., Craig, S., Sodroski, J.
(2000). The Level of CD4 Expression Limits Infection of Primary Rhesus Monkey Macrophages by a T-Tropic Simian Immunodeficiency Virus and Macrophagetropic Human Immunodeficiency Viruses. J. Virol.
74: 10984-10993
[Abstract]
[Full Text]
-
Dejucq, N.
(2000). HIV-1 replication in CD4+ T cell lines: the effects of adaptation on co-receptor use, tropism, and accessory gene function. J. Leukoc. Biol.
68: 331-337
[Abstract]
[Full Text]
-
Zhang, Y.-j., Lou, B., Lal, R. B., Gettie, A., Marx, P. A., Moore, J. P.
(2000). Use of Inhibitors To Evaluate Coreceptor Usage by Simian and Simian/Human Immunodeficiency Viruses and Human Immunodeficiency Virus Type 2 in Primary Cells. J. Virol.
74: 6893-6910
[Abstract]
[Full Text]
-
Sharron, M., Pohlmann, S., Price, K., Lolis, E., Tsang, M., Kirchhoff, F., Doms, R. W., Lee, B.
(2000). Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood
96: 41-49
[Abstract]
[Full Text]
-
Pöhlmann, S., Lee, B., Meister, S., Krumbiegel, M., Leslie, G., Doms, R. W., Kirchhoff, F.
(2000). Simian Immunodeficiency Virus Utilizes Human and Sooty Mangabey but Not Rhesus Macaque STRL33 for Efficient Entry. J. Virol.
74: 5075-5082
[Abstract]
[Full Text]
-
Scoggins, R. M., Taylor, J. R. Jr., Patrie, J., van't Wout, A. B., Schuitemaker, H., Camerini, D.
(2000). Pathogenesis of Primary R5 Human Immunodeficiency Virus Type 1 Clones in SCID-hu Mice. J. Virol.
74: 3205-3216
[Abstract]
[Full Text]
-
Murphy, P. M., Baggiolini, M., Charo, I. F., Hebert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. J., Power, C. A.
(2000). International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors. Pharmacol. Rev.
52: 145-176
[Abstract]
[Full Text]
-
Schramm, B., Penn, M. L., Speck, R. F., Chan, S. Y., De Clercq, E., Schols, D., Connor, R. I., Goldsmith, M. A.
(2000). Viral Entry through CXCR4 Is a Pathogenic Factor and Therapeutic Target in Human Immunodeficiency Virus Type 1 Disease. J. Virol.
74: 184-192
[Abstract]
[Full Text]
-
Shimizu, N., Soda, Y., Kanbe, K., Liu, H.-y., Mukai, R., Kitamura, T., Hoshino, H.
(2000). A Putative G Protein-Coupled Receptor, RDC1, Is a Novel Coreceptor for Human and Simian Immunodeficiency Viruses. J. Virol.
74: 619-626
[Abstract]
[Full Text]
-
Murakami, T., Zhang, T.-Y., Koyanagi, Y., Tanaka, Y., Kim, J., Suzuki, Y., Minoguchi, S., Tamamura, H., Waki, M., Matsumoto, A., Fujii, N., Shida, H., Hoxie, J. A., Peiper, S. C., Yamamoto, N.
(1999). Inhibitory Mechanism of the CXCR4 Antagonist T22 against Human Immunodeficiency Virus Type 1 Infection. J. Virol.
73: 7489-7496
[Abstract]
[Full Text]
-
Singh, A., Besson, G., Mobasher, A., Collman, R. G.
(1999). Patterns of Chemokine Receptor Fusion Cofactor Utilization by Human Immunodeficiency Virus Type 1 Variants from the Lungs and Blood. J. Virol.
73: 6680-6690
[Abstract]
[Full Text]
-
Dumonceaux, J., Chanel, C., Valente, S., Quivet, L., Briand, P., Hazan, U.
(1999). Mutations in the env gene of human immunodeficiency virus type 1 NDK isolates and the use of African green monkey CXCR4 as a co-receptor in COS-7 cells. J. Gen. Virol.
80: 1975-1982
[Abstract]
[Full Text]
-
Blanpain, C., Lee, B., Vakili, J., Doranz, B. J., Govaerts, C., Migeotte, I., Sharron, M., Dupriez, V., Vassart, G., Doms, R. W., Parmentier, M.
(1999). Extracellular Cysteines of CCR5 Are Required for Chemokine Binding, but Dispensable for HIV-1 Coreceptor Activity. J. Biol. Chem.
274: 18902-18908
[Abstract]
[Full Text]
-
Schenten, D., Marcon, L., Karlsson, G. B., Parolin, C., Kodama, T., Gerard, N., Sodroski, J.
(1999). Effects of Soluble CD4 on Simian Immunodeficiency Virus Infection of CD4-Positive and CD4-Negative Cells. J. Virol.
73: 5373-5380
[Abstract]
[Full Text]
-
Howard, O. M. Z., Shirakawa, A.-K., Turpin, J. A., Maynard, A., Tobin, G. J., Carrington, M., Oppenheim, J. J., Dean, M.
(1999). Naturally Occurring CCR5 Extracellular and Transmembrane Domain Variants Affect HIV-1 Co-receptor and Ligand Binding Function. J. Biol. Chem.
274: 16228-16234
[Abstract]
[Full Text]
-
Shimizu, N., Soda, Y., Kanbe, K., Liu, H.-Y., Jinno, A., Kitamura, T., Hoshino, H.
(1999). An Orphan G Protein-Coupled Receptor, GPR1, Acts as a Coreceptor To Allow Replication of Human Immunodeficiency Virus Types 1 and 2 in Brain-Derived Cells. J. Virol.
73: 5231-5239
[Abstract]
[Full Text]
-
Mosier, D. E., Picchio, G. R., Gulizia, R. J., Sabbe, R., Poignard, P., Picard, L., Offord, R. E., Thompson, D. A., Wilken, J.
(1999). Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants. J. Virol.
73: 3544-3550
[Abstract]
[Full Text]
-
Edinger, A. L., Blanpain, C., Kunstman, K. J., Wolinsky, S. M., Parmentier, M., Doms, R. W.
(1999). Functional Dissection of CCR5 Coreceptor Function through the Use of CD4-Independent Simian Immunodeficiency Virus Strains. J. Virol.
73: 4062-4073
[Abstract]
[Full Text]
-
Doranz, B. J., Orsini, M. J., Turner, J. D., Hoffman, T. L., Berson, J. F., Hoxie, J. A., Peiper, S. C., Brass, L. F., Doms, R. W.
(1999). Identification of CXCR4 Domains That Support Coreceptor and Chemokine Receptor Functions. J. Virol.
73: 2752-2761
[Abstract]
[Full Text]
-
Zhang, Y.-j., Moore, J. P.
(1999). Will Multiple Coreceptors Need To Be Targeted by Inhibitors of Human Immunodeficiency Virus Type 1 Entry?. J. Virol.
73: 3443-3448
[Abstract]
[Full Text]
-
Chan, S. Y., Speck, R. F., Power, C., Gaffen, S. L., Chesebro, B., Goldsmith, M. A.
(1999). V3 Recombinants Indicate a Central Role for CCR5 as a Coreceptor in Tissue Infection by Human Immunodeficiency Virus Type 1. J. Virol.
73: 2350-2358
[Abstract]
[Full Text]
-
Kimata, J. T., Gosink, J. J., KewalRamani, V. N., Rudensey, L. M., Littman, D. R., Overbaugh, J.
(1999). Coreceptor Specificity of Temporal Variants of Simian Immunodeficiency Virus Mne. J. Virol.
73: 1655-1660
[Abstract]
[Full Text]
-
Albright, A. V., Shieh, J. T. C., Itoh, T., Lee, B., Pleasure, D., O'Connor, M. J., Doms, R. W., Gonzalez-Scarano, F.
(1999). Microglia Express CCR5, CXCR4, and CCR3, but of These, CCR5 Is the Principal Coreceptor for Human Immunodeficiency Virus Type 1 Dementia Isolates. J. Virol.
73: 205-213
[Abstract]
[Full Text]
-
Zhang, Y.-j., Dragic, T., Cao, Y., Kostrikis, L., Kwon, D. S., Littman, D. R., KewalRamani, V. N., Moore, J. P.
(1998). Use of Coreceptors Other Than CCR5 by Non-Syncytium-Inducing Adult and Pediatric Isolates of Human Immunodeficiency Virus Type 1 Is Rare In Vitro. J. Virol.
72: 9337-9344
[Abstract]
[Full Text]
-
Miyagi, T., Chuang, L. F., Doi, R. H., Carlos, M. P., Torres, J. V., Chuang, R. Y.
(2000). Morphine Induces Gene Expression of CCR5 in Human CEM x174 Lymphocytes. J. Biol. Chem.
275: 31305-31310
[Abstract]
[Full Text]
-
Farzan, M., Vasilieva, N., Schnitzler, C. E., Chung, S., Robinson, J., Gerard, N. P., Gerard, C., Choe, H., Sodroski, J.
(2000). A Tyrosine-sulfated Peptide Based on the N Terminus of CCR5 Interacts with a CD4-enhanced Epitope of the HIV-1 gp120 Envelope Glycoprotein and Inhibits HIV-1 Entry. J. Biol. Chem.
275: 33516-33521
[Abstract]
[Full Text]
-
Hosoya, M., Kawamata, Y., Fukusumi, S., Fujii, R., Habata, Y., Hinuma, S., Kitada, C., Honda, S., Kurokawa, T., Onda, H., Nishimura, O., Fujino, M.
(2000). Molecular and Functional Characteristics of APJ. TISSUE DISTRIBUTION OF mRNA AND INTERACTION WITH THE ENDOGENOUS LIGAND APELIN. J. Biol. Chem.
275: 21061-21067
[Abstract]
[Full Text]